ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Aug 27, 2020 17:05 JST
Source:
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Launched an Equity Incentive Plan to Inject New Impetus for the Company's Growth
HONG KONG, Aug 27, 2020 - (ACN Newswire) - Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that on 26 August 2020, the Company granted a total of 94,656,000 share options (the "Share Options") to the eligible participants of the Company (the "Grantees") to subscribe for a total of 94,656,000 ordinary shares of HK$0.01 each in the share capital of the Company (the "Shares") pursuant to the share option scheme of the Company adopted on 24 October 2017, subject to the acceptance by the Grantees.
Among the total of 94,656,000 Share Options granted, 19,000,000 Share Options were granted to five Directors, and the remaining 75,656,000 Share Options were granted to eligible participants who are employees of the Company. The exercise price of the share options granted HK$0.972 per share, closing price of the shares on the date of grant was HK$0.900 per share, average closing price of the shares for the five business days immediately preceding the date of grant was HK$0.972 per share. Validity period of the options start from 26 August 2020 to 25 August 2030 (both days inclusive).
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical is a pharmaceutical group with 21 subsidiaries and integrated R&D, production and marketing and sales capabilities. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has formed a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects currently. More than 300 patents on innovative drugs were granted in China and over 80 are PCT patents, covering pipeline projects including important areas of diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis etc.
For more information about Sihuanpharm, please visit the company website
https://www.sihuanpharm.com/
.
Source: Sihuan Pharmaceutical Holdings Group Ltd.
Sectors: Daily Finance, Daily News
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
Construction Begins on New Toyota Tokyo Head Office in Shinagawa, to Open in FY2030
May 27, 2025 14:31 JST
JCB partners with PayXpert to expand in-store card acceptance for international shoppers and travellers coming to Europe and in the UK
May 27, 2025 12:00 JST
JCB Collaborates with Noage International to Expand Advanced Medical Tourism Program in Japan for Affluent Indonesians
May 27, 2025 10:00 JST
Ministry of Energy of Uzbekistan and MHI Sign MOU to Conduct Joint Study of Decarbonization Strategy for Uzbekistan
May 27, 2025 09:49 JST
Fujitsu launches second corporate venture capital fund to drive innovation and achieve a sustainable society
May 26, 2025 18:27 JST
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV
May 22, 2025 13:35 JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21, 2025 15:00 JST
New RAV4 Makes World Premiere in Japan
May 21, 2025 14:09 JST
Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer
May 21, 2025 14:00 JST
MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines
May 20, 2025 13:51 JST
MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT
May 19, 2025 16:14 JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16, 2025 17:21 JST
More Latest Release >>
Related Release
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical: The NDA of the New Drug, independently developed for the treatment of advanced breast cancer was accepted by NMPA
October 17 2023 16:01 JST
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
October 13 2023 18:07 JST
Sihuan Pharmaceutical (0460.HK) Announces 2023 Interim Results, Revenue amounted to RMB1,055.7 million
August 31 2023 13:50 JST
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval For Clinical Trial
July 05 2023 09:49 JST
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
June 27 2023 13:00 JST
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development, Presents major research results of birociclib, the start product, at the international stage in ASCO
June 08 2023 21:18 JST
Sihuan Pharmaceutical (0460.HK) Announces 2022 Annual Results
March 24 2023 19:16 JST
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical Successfully Completes A+ Round of Financing, Accelerating the Layout of Diabetes and Complications
January 04 2023 09:55 JST
Sihuan Pharmaceutical (0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' in China's Medical Aesthetics Industry
August 11 2021 16:55 JST
Sihuan Pharmaceutical Announces 2020 Interim Results
August 25 2020 21:26 JST
More Press release >>